Academic Journals Database
Disseminating quality controlled scientific knowledge

Anthracycline-related cardiotoxicity: risk factors and therapeutic options in childhood cancers

ADD TO MY LIST
 
Author(s): NADIA PUMA | ANTONIO RUGGIERO | VITA RIDOLA | PALMA MAURIZI | ILARIA LAZZARESCHI | GIORGIO ATTINÀ | STEFANO MASTRANGELO | GABRIELLA DE ROSA | RICCARDO RICCARDI

Journal: Signa Vitae
ISSN 1334-5605

Volume: 3;
Issue: 1;
Start page: 30;
Date: 2008;
VIEW PDF   PDF DOWNLOAD PDF   Download PDF Original page

Keywords: anthracycline | cardiotoxicity | childhood cancer | risk factors | prevention | acute heart failure

ABSTRACT
Anthracyclines play an important role in chemotherapeutic regimens for a wide spectrum of childhood tumors, but they can cause cytotoxic damage to cardiac cells, especially in combination with radiotherapy. Furthermore, cardiotoxicity increases with the cumulative dose and may lead to congestive heart failure and cardiomyopathy. Other factors, including age, pre-existing cardiac disease, length of follow-up, gender, route of administration, concomitant exposure to some chemotherapeutic drugs, trisomy 21 and black race, play a role in increasing the risk of cardiac dysfunction. The prevention of anthracycline-induced cardiotoxicity is mandatory as children are expected to survive for decades after being cured of their cancer. The purpose of this work is to point out the major risk factors of cardiotoxicity in children and to summarize some strategies to limit or prevent this complication and to treat the development of acute heart failure.
Why do you need a reservation system?      Save time & money - Smart Internet Solutions